Aspirin and intracerebral hemorrhage
Where are we now?
Summary
For the past 3 decades, aspirin has been widely used for prevention of ischemic stroke and myocardial infarction. Although the evidence supporting the effectiveness of aspirin in prevention of vascular events is clear, data regarding the risk of acute and recurrent intracerebral hemorrhage related to the use of this medication have been conflicting. We review past and contemporary data on aspirin use in relation to intracerebral hemorrhage.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
REFERENCES
1.
Sneader W. The discovery of aspirin: a reappraisal. BMJ 2000;321:1591–1594.
2.
Weiss HJ, Aledort LM. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 1967;2:495–497.
3.
Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.
4.
Albers GW. Antithrombotic agents in cerebral ischemia. Am J Cardiol 1995;75:34B–38B.
5.
Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255–258.
6.
Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206–1218.
7.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349–360.
8.
Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris: The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421–1425.
9.
International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569–1581.
10.
CAST (Chinese Acute Stroke Trial) collaborative group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641–1649.
11.
Juvela S, Hillbom M, Palomäki H. Risk factors for spontaneous intracerebral hemorrhage. Stroke 1995;26:1558–1564.
12.
García-Rodríguez LA, Gaist D, Morton J, Cookson C, González-Pérez A. Antithrombotic drugs and risk of hemorrhagic stroke in the general population. Neurology 2013;81:566–574.
13.
Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke 2005;36:1801–1807.
14.
Boysen G. Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. J Intern Med 1999;246:239–245.
15.
The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345–1349.
16.
Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases: American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388–391.
17.
Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:517–584.
18.
Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–1304.
19.
Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000;57:326–332.
20.
Viswanathan A, Rakich SM, Engel C, et al. Antiplatelet use after intracerebral hemorrhage. Neurology 2006;66:206–209.
21.
Huhtakangas J, Löppönen P, Tetri S, et al. Predictors for recurrent primary intracerebral hemorrhage: a retrospective population-based study. Stroke 2013;44:585–590.
22.
Wong KS, Mok V, Lam WW, et al. Aspirin-associated intracerebral hemorrhage: clinical and radiologic features. Neurology 2000;54:2298–2301.
23.
Naka H, Nomura E, Kitamura J, Imamura E, Wakabayashi S, Matsumoto M. Antiplatelet therapy as a risk factor for microbleeds in intracerebral hemorrhage patients: analysis using specific antiplatelet agents. J Stroke Cerebrovasc Dis 2013;22:834–840.
24.
Soo YO, Yang SR, Lam WW, et al. Risk vs benefit of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds. J Neurol 2008;255:1679–1686.
25.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 1998;351:1755–1762.
26.
Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005;95:1218–1222.
27.
Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044–1054.
28.
Broderick J, Brott T, Duldner J, Tomsick T, Huster G. Volume of intracerebral hemorrhage: a powerful and easy-to-use predictor of 30-day mortality. Stroke 1993;24:987–993.
29.
Lauer A, Schlunk F, Van Cott EM, Steinmetz H, Lo EH, Foerch C. Antiplatelet pretreatment does not increase hematoma volume in experimental intracerebral hemorrhage. J Cereb Blood Flow Metab 2011;31:1736–1742.
30.
Toyoda K, Okada Y, Minematsu K, et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology 2005;68:1000–1004.
Information & Authors
Information
Published In
Neurology® Clinical Practice
Volume 5 • Number 1 • February 2015
Pages: 11-16
Copyright
© 2015 American Academy of Neurology.
Publication History
Published online: November 5, 2014
Published in print: February 2015
Disclosures
R. Behrouz serves as a Contributing Editor to Practical Neurology and as an Associate Editor for BioMed Central Neurology and has participated in medico-legal cases. C.M. Miller reports no disclosures. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Study Funding
No targeted funding reported.
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Successful management of mycotic visceral aneurysms in a LVAD patient and navigating LVAD postoperative challenges, Journal of Vascular Surgery Cases, Innovations and Techniques, 11, 2, (101715), (2025).https://doi.org/10.1016/j.jvscit.2024.101715
- Clinical Characteristics, Treatment Outcomes, and its Predictors Among Hospitalized Stroke Patients in Ambo University Referral Hospital, West Ethiopia: A Retrospective Hospital-Based Study, Vascular Health and Risk Management, Volume 16, (591-604), (2021).https://doi.org/10.2147/VHRM.S287465
- Relationship between aspirin use and subarachnoid hemorrhage: A systematic Review and meta-analysis, Clinical Neurology and Neurosurgery, 200, (106320), (2021).https://doi.org/10.1016/j.clineuro.2020.106320
- Stroke Characteristics and Outcomes of Adult Patients in Northwest Ethiopia, Frontiers in Neurology, 11, (2020).https://doi.org/10.3389/fneur.2020.00428
- Should Aspirin Be Prescribed to Prevent Recurrence in Nonarteritic Anterior Ischemic Optic Neuropathy?, Journal of Neuro-Ophthalmology, 40, 3, (428-433), (2020).https://doi.org/10.1097/WNO.0000000000000930
- Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective, Biochemical Pharmacology, 180, (114147), (2020).https://doi.org/10.1016/j.bcp.2020.114147
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.